4-(1-methylpiperidin-4-yl)-N-(5-(pyridin-3-ylmethoxy)-1H-pyrazolo[4,3-b]pyridin-3-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzamide | 1392151-18-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(1-methylpiperidin-4-yl)-N-(5-(pyridin-3-ylmethoxy)-1H-pyrazolo[4,3-b]pyridin-3-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzamide
• 英文别名: 4-(1-methylpiperidin-4-yl)-2-[oxan-4-yl-(2,2,2-trifluoroacetyl)amino]-N-[5-(pyridin-3-ylmethoxy)-1H-pyrazolo[4,3-b]pyridin-3-yl]benzamide
• CAS: 1392151-18-6
• 化学式: C₃₂H₃₄F₃N₇O₄
• 分子量: 637.662
• InChiKey: WGQGQSNRFUQGFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  46
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  126
• 氢给体数：
  2
• 氢受体数：
  11

文献信息

• Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
  申请人：PIERRE FABRE MEDICAMENT

  公开号：EP2689779A1

  公开（公告）日：2014-01-29

  The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.

  本发明涉及具有以下公式(I)的化合物： 或其药用可接受的盐或溶剂化物，其互变异构体，或其立体异构体或立体异构体混合物，以任何比例，如对映体混合物，尤其是外消旋混合物，以及包含该化合物的药物组合物，用于治疗与至少一种Trk蛋白过度表达相关的癌症。
• Derivatives of azaindoles or diazaindoles for treating pain
  申请人：PIERRE FABRE MEDICAMENT

  公开号：EP2689778A1

  公开（公告）日：2014-01-29

  The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; for use in the treatment of pain.

  本发明涉及具有以下公式(I)的化合物： 或其药用可接受的盐或溶剂化物，其同分异构体，或其立体异构体或立体异构体混合物，以任何比例，例如对映体混合物，尤其是外消旋混合物；用于治疗疼痛。
• DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT
  申请人：Kaloun El Bachir

  公开号：US20130172360A1

  公开（公告）日：2013-07-04

  The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; as well as to the use of same as a drug, notably intended for the treatment of cancer, inflammation and neurodegenerative diseases such as Alzheimer's disease; to the use of same as a kinase inhibitor; to the pharmaceutical compositions comprising same; and to methods for the preparation of same.

  本发明涉及以下式（I）的化合物，或其药学上可接受的盐或溶剂、同分异构体、立体异构体或立体异构体混合物，如对映体混合物，特别是外消旋混合物；以及将其用作药物，特别是用于治疗癌症、炎症和神经退行性疾病，如阿尔茨海默病的用途；将其用作激酶抑制剂的用途；包含其的制药组合物；以及制备其的方法。
• DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN
  申请人：PIERRE FABRE MEDICAMENT

  公开号：US20150190394A1

  公开（公告）日：2015-07-09

  The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; for use in the treatment of pain.

  本发明涉及以下式(I)的化合物，或其药学上可接受的盐或溶剂，其互变异构体，或其立体异构体或立体异构体混合物，比例不限，例如对映体混合物，特别是外消旋混合物；用于治疗疼痛。
• DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING Trk
  申请人：PIERRE FABRE MEDICAMENT

  公开号：US20150266880A1

  公开（公告）日：2015-09-24

  The present invention relates to a compound of following formula (I) or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.

  本发明涉及以下式(I)的化合物或其药学上可接受的盐或溶剂、同分异构体、立体异构体或同分异构体混合物，如对映体混合物，特别是外消旋混合物，以及包含这种化合物的制药组合物，用于治疗与至少一种Trk蛋白过度表达相关的癌症。